This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kamasani, U. Articles by Prendergast, G. C. Search for Related Content PubMed PubMed Citation Articles by Kamasani, U. Articles by Prendergast, G. C.

Cyclin B1 Is a Critical Target of RhoB in the Cell Suicide Program Triggered by Farnesyl Transferase Inhibition

¹ Lankenau Institute for Medical Research, Wynnewood Pennsylvania; ² Children’s Hospital of Pittsburgh, Section of Hematology/Oncology, Pittsburgh, Pennsylvania; and ³ Department of Pathology, Anatomy, and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

Farnesyl transferase inhibitors (FTIs) have displayed limited efficacy in clinical trials, possibly because of their relatively limited cytotoxic effects against most human cancer cells. Therefore, efforts to leverage the clinical utility of FTIs may benefit from learning how these agents elicit p53-independent apoptosis in mouse models of cancer. Knockout mouse studies have established that gain of the geranylgeranylated isoform of the small GTPase RhoB is essential for FTI to trigger apoptosis. Here we demonstrate that Cyclin B1 is a crucial target for suppression by RhoB in this death program. Steady-state levels of Cyclin B1 and its associated kinase Cdk1 were suppressed in a RhoB-dependent manner in cells fated to undergo FTI-induced apoptosis. These events were not derivative of cell cycle arrest, because they did not occur in cells fated to undergo FTI-induced growth inhibition. Mechanistic investigations indicated that RhoB mediated transcriptional suppression but also accumulation of Cyclin B1 in the cytosol at early times after FTI treatment, at a time before the subsequent reduction in steady-state protein levels. Enforcing Cyclin B1 expression attenuated apoptosis but not growth inhibition triggered by FTI. Moreover, enforcing Cyclin B1 abolished FTI antitumor activity in graft assays. These findings suggest that Cyclin B1 suppression is a critical step in the mechanism by which FTI triggers apoptosis and robust antitumor efficacy. Our findings suggest that Cyclin B1 suppression may predict favorable clinical responses to FTI, based on cytotoxic susceptibility, and they suggest a rational strategy to address FTI nonresponders by coinhibition of Cdk1 activity.

This article has been cited by other articles:

				H. DOI, M.-A. SHIBATA, E. SHIBATA, J. MORIMOTO, Y. AKAO, M. IINUMA, N. TANIGAWA, and Y. OTSUKI Panaxanthone Isolated from Pericarp of Garcinia mangostana L. Suppresses Tumor Growth and Metastasis of a Mouse Model of Mammary Cancer Anticancer Res, July 1, 2009; 29(7): 2485 - 2495. [Abstract] [Full Text] [PDF]

				J. E. Karp, K. Flatten, E. J. Feldman, J. M. Greer, D. A. Loegering, R. M. Ricklis, L. E. Morris, E. Ritchie, B. D. Smith, V. Ironside, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide Blood, May 14, 2009; 113(20): 4841 - 4852. [Abstract] [Full Text] [PDF]

				L. A. Marlow, L. A. Reynolds, A. S. Cleland, S. J. Cooper, M. L. Gumz, S. Kurakata, K. Fujiwara, Y. Zhang, T. Sebo, C. Grant, et al. Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth Cancer Res., February 15, 2009; 69(4): 1536 - 1544. [Abstract] [Full Text] [PDF]

				A. D. Basso, P. Kirschmeier, and W. R. Bishop Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors J. Lipid Res., January 1, 2006; 47(1): 15 - 31. [Abstract] [Full Text] [PDF]

				B. F. Goemans, C. M. Zwaan, A. Harlow, A. H. Loonen, B. E. S. Gibson, K. Hahlen, D. Reinhardt, U. Creutzig, M. C. Heinrich, and G. J. L. Kaspers In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets Blood, November 15, 2005; 106(10): 3532 - 3537. [Abstract] [Full Text] [PDF]

				J. Pan and S.-C. J. Yeung Recent Advances in Understanding the Antineoplastic Mechanisms of Farnesyltransferase Inhibitors Cancer Res., October 15, 2005; 65(20): 9109 - 9112. [Abstract] [Full Text] [PDF]

				J. Pan, M. She, Z.-X. Xu, L. Sun, and S.-C. J. Yeung Farnesyltransferase Inhibitors Induce DNA Damage via Reactive Oxygen Species in Human Cancer Cells Cancer Res., May 1, 2005; 65(9): 3671 - 3681. [Abstract] [Full Text] [PDF]